A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (NCT07284849)
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (9 items).
Location: Mitchell Cancer Institute — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- MSI-H/dMMR per historical data in the medical record.
- BRAF V600E mutation per historical data in the medical record.
- Untreated and/or progressing CNS metastases.
- History of other malignancy within 2 years.
- Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
- Active autoimmune disease that has required systemic treatment in the past 2 years.
- Significant concurrent and/or uncontrolled medical condition.
- History of organ transplant, including allogeneic stem cell transplantation. Other protocol-defined inclusion/exclusion criteria apply.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (254 Sites)
Showing the first 25 of 254 sites.
- Mitchell Cancer Institute — Mobile, Alabama
- The University of Arizona Cancer Center — Tucson, Arizona
- Roche Tissue Diagnostics, Companion Diagnostics — Tucson, Arizona
- Memorial Care Orange Coast Medical Center — Fountain Valley, California
- Providence Medical Foundation — Fullerton, California
- Cancer & Blood Research Center — Los Alamitos, California
- University of California Los Angeles Health — Los Angeles, California
- Sarah Cannon Research Institute Scri Oncology Partners — Aurora, Colorado
- Hartford Hospital — Hartford, Connecticut
- George Washington University — Washington D.C., District of Columbia
- Florida Oncology & Hematology — Fort Myers, Florida
- University of Florida Health — Gainesville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Advent Health — Orlando, Florida
- Orlando Health Cancer Institute Downtown Orlando — Orlando, Florida
- Ascension Sacred Heart Pensacola — Pensacola, Florida
- Tampa General Hospital-Cancer Institute — Tampa, Florida
- Piedmont Cancer Institute — Locust Grove, Georgia
- University of Hawaii Cancer Center — Honolulu, Hawaii
- St Lukes Mountain States Tumor Institute Msti Boise — Boise, Idaho
- Sih Cancer Institute — Carterville, Illinois
- University of Illinois Cancer Center — Chicago, Illinois
- Endeavor Health — Evanston, Illinois
- Springfield Clinic — Springfield, Illinois
- Community Health Network, Inc. — Indianapolis, Indiana
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CRC (Colorectal Cancer)
Explore by condition: All CRC (Colorectal Cancer) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.